Joaquim Bellmunt
霍阿金·贝尔蒙特
MD, PhD
Professor of Medicine, Harvard Medical School; Director, Bladder Cancer Research, Beth Israel Deaconess Medical Center哈佛医学院医学教授，贝斯以色列女执事医疗中心膀胱癌研究主任
👥Biography 个人简介
Joaquim Bellmunt, MD, PhD is Professor of Medicine at Harvard Medical School and Director of Bladder Cancer Research at Beth Israel Deaconess Medical Center. He is a pioneering figure in the clinical development of immunotherapy for urothelial carcinoma, most notably as a principal investigator of KEYNOTE-045—the landmark phase III trial that demonstrated pembrolizumab significantly improved overall survival compared to investigator-choice chemotherapy in platinum-pretreated advanced urothelial carcinoma, establishing PD-1 inhibition as a new second-line standard of care. Prior to his work at Harvard, Dr. Bellmunt led the genitourinary oncology program at Hospital del Mar in Barcelona, where he developed the widely used Bellmunt prognostic model for advanced urothelial carcinoma, which stratifies patients by performance status, hemoglobin, and the presence of visceral metastases. He has contributed to more than 200 clinical trials and has been a key architect of both ESMO and EAU guidelines for bladder cancer. His translational work includes characterization of genomic alterations predicting platinum sensitivity, and identification of immune gene expression signatures associated with pembrolizumab response.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
KEYNOTE-045 — Pembrolizumab Establishes Second-Line Standard in Advanced Bladder Cancer
Served as a principal investigator for KEYNOTE-045, the phase III trial demonstrating that pembrolizumab significantly improved overall survival versus investigator-choice chemotherapy (paclitaxel, docetaxel, or vinflunine) in platinum-pretreated advanced urothelial carcinoma, leading to FDA approval of the first checkpoint inhibitor in this setting.
Bellmunt Prognostic Model for Advanced Urothelial Carcinoma
Developed and validated the Bellmunt prognostic score—a three-variable model incorporating ECOG performance status, hemoglobin, and presence of liver metastases—which became the standard risk stratification tool used in global bladder cancer clinical trials for more than 15 years.
First-Line Immunotherapy Strategy and PD-L1 Biomarker Refinement
Contributed to the clinical evaluation of pembrolizumab and atezolizumab as first-line monotherapy options in cisplatin-ineligible advanced urothelial carcinoma, and participated in refining PD-L1 combined positive score and immune cell score as complementary biomarkers for patient selection.
Genomic Predictors of Platinum Sensitivity in Bladder Cancer
Conducted translational analyses identifying DNA damage response (DDR) gene alterations—including mutations in ERCC2 and ATM—as predictors of cisplatin sensitivity in muscle-invasive and advanced bladder cancer, providing a genomic rationale for neoadjuvant platinum-based chemotherapy selection.
Representative Works 代表性著作
Pembrolizumab as second-line therapy for advanced urothelial carcinoma (KEYNOTE-045)
New England Journal of Medicine (2017)
Phase III KEYNOTE-045 trial establishing pembrolizumab as the new standard of care in platinum-pretreated advanced urothelial carcinoma, demonstrating superior overall survival versus chemotherapy.
Prognostic model for predicting survival in patients with metastatic urothelial cancer treated with platinum-based chemotherapy
Journal of Clinical Oncology (2010)
Validation and dissemination of the Bellmunt prognostic model for advanced urothelial carcinoma, adopted as the standard risk stratification tool in clinical trials.
Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors
Nature Genetics (2014)
Landmark translational study linking somatic ERCC2 mutations to cisplatin sensitivity and a characteristic mutational signature in bladder cancer, with implications for neoadjuvant chemotherapy selection.
Vinflunine plus best supportive care versus best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract
Annals of Oncology (2009)
Phase III trial of vinflunine in second-line urothelial carcinoma, previously the European regulatory standard before immunotherapy approval, led by Dr. Bellmunt.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 霍阿金·贝尔蒙特 的研究动态
Follow Joaquim Bellmunt's research updates
留下邮箱，当我们发布与 Joaquim Bellmunt（Beth Israel Deaconess Medical Center / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment